Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value Peer-spectives
Filter by Topic
ASCO’s Value Framework
Commentary
Employers’ Perspective
Letter to our Readers
Oncologist–Patient Communication
Patient Communication
Patient Perspective
Payer’s Perspective
Practice Management
Testimonials
The Patient Perspective
Value in Oncology
Value Propositions
VBCC Perspectives
Inaugural Employer-Provider Interface Council Conference Explores Value in Healthcare
By
Zachary R. Babcock, PhD
;
F. Randy Vogenberg, PhD, RPh, FASHP
Employers’ Perspective
,
Value Peer-spectives
October 2019, Vol 10, No 5
In today’s fast-paced healthcare environment, managing health benefits requires dexterity, foresight, and collaboration. At the inaugural multistakeholder Employer-Provider Interface Council (EPIC) of the Hospital Quality Foundation interactive Leadership Conference that took place on June 11, 2019, the relationships among employer plan sponsors, employee healthcare consumers, and healthcare providers were explored. To understand how health benefits are managed to deliver value to stakeholders, several speakers discussed the importance of how to define and derive value in the rapidly changing healthcare industry. Each presentation was followed by reactions from a stakeholders panel from various segments of the healthcare industry, including consumer advocacy, employer, payer, government, and provider.
Read Article
Value Propositions
Value Propositions
,
Value Peer-spectives
September 2010, Vol 1, No 4
dding trastuzumab to standard cisplatinum/fluoropyrimidine chemotherapy for patients with HER2-positive advanced gastric cancer results in a median survival of 13.8 months, compared with 11.1 months with chemotherapy alone, according to a new study (
Lancet
. 2010;376 [9742]:687-97. Epub 2010 Aug 19).
Read Article
Strategic Insights on Midsize Employers and Cancer Care Coverage
By
Bincy Augustine, PharmD
;
F. Randy Vogenberg, PhD, RPh, FASHP
Employers’ Perspective
,
Value Peer-spectives
April 2019, Vol 10, No 2
It is no surprise that healthcare costs are at an all-time high and continue to take center stage in political, social, and economic debates. Employers, as health plan sponsors and as purchasers of care, are looking to take matters into their own hands and tackle the problem through innovative reimbursement strategies. Not all employers, however, are built the same. Experiences in controlling healthcare costs vary between small and large employers. The most affected employers are in the middle and are known as midsize employers.
Read Article
Drug Costs, and Employers as Purchasers of Care
By
F. Randy Vogenberg, PhD, RPh, FASHP
Employers’ Perspective
,
Value Peer-spectives
April 2017, Vol 8, No 2
Unlike other countries around the world, the United States does not regulate or negotiate drug prices. In general, the European Union members (eg, United Kingdom, France, Germany), Australia, and other countries incorporate pricing at the time of new drug approval, and allow the use of a new drug when it provides a significant clinical benefit over existing drugs, relative to the drug price.
Read Article
Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value
By
James T. Kenney, RPh, MBA
Payer’s Perspective
,
Value Peer-spectives
February 2017, Vol 8, No 1
The 2016 American Society of Hematology (ASH) meeting provided insight into new treatment options and mechanism of action choices for hematologic cancers. Health plans need to continue to expand their knowledge and expertise in all cancer types to maintain the ability to manage and apply coverage criteria appropriately as FDA approvals continue to increase in oncology.
Read Article
Employers Look to Manage the Benefits of Specialty Pharmacy
By
Wayne Kuznar
Employers’ Perspective
,
Specialty Pharmacy
,
Value Peer-spectives
December 2016, Vol 7, No 11
Washington, DC—Employers recognize that oncology care is expensive, and they are shifting their focus on cost management. As such, employers are seeking approaches to determine which drugs and health plan designs will help them manage pharmacy and medical costs to improve patient outcomes, said F. Randy Vogenberg, PhD, RPh, Partner, Access Market Intelligence, and National Institute of Collaborative Healthcare, Greenville, SC, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Value Propositions - October 2016
Value Propositions
,
Value Peer-spectives
October 2016, Vol 7, No 9
Read Article
Guidelines and Pathway: Link to Benefit Design by Employers
By
Kristin Jarrell, PharmD
;
Michael Toscani, PharmD
Employers’ Perspective
,
Value Peer-spectives
September 2016, Vol 7, No 8
In today’s changing oncology landscape, the quality and value of cancer care have become increasingly integrated. With the rising costs of cancer treatment, payers and policymakers aim to better define value, as well as to educate patients about their therapeutic options. Insurers and payers have implemented a variety of strategies to control costs at the behest of employer plan sponsors, including utilizing oncology clinical pathways.
Read Article
The Challenge of Balancing Access to and Paying for New, High-Cost Cancer Therapies
By
James T. Kenney, RPh, MBA
Payer’s Perspective
,
Value Peer-spectives
August 2016, Vol 7, No 7, Special Issue: Payers’ Perspectives in Oncology
Many significant and interesting topics highlighted at ASCO 2016 are discussed in this publication, covering clinical, safety, and economic issues related to cancer therapies.
Read Article
Incorporating Patient and Employer Perspectives into Value-Based Cancer Therapy Decision-Making
By
Joseph P. Fulginiti, PharmD
;
Melissa S. Pavilack, PharmD
Employers’ Perspective
,
Value-Based Care
,
Value Peer-spectives
July 2016, Vol 7, No 6
“Value” in healthcare has been defined as outcomes relative to cost. Determining the value of a healthcare benefit remains difficult and complex for many stakeholders. With the increasing cost of cancer therapies, value has become an important topic of conversation for patients, healthcare providers, self-funded plan sponsors (employers), and payers.
Read Article
Page 1 of 16
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma